Cempra’s Antibiotic Likely Needs Bigger Trial – But Might Be Able To Do It In Phase IV

FDA advisory committee votes 7-6 that the strong efficacy profile of Solithera (solithromycin) outweighs its unknown safety risks; panels agreed that more data was needed, but were split on whether it was needed pre- or post-approval.

Cempra Inc.'s community acquired bacterial pneumonia (CABP) antibiotic Solithera (solithromycin) barely squeaked passed an FDA advisory panel, but the drug will likely be forced to conduct another clinical trial of the drug regardless of the approval outcome.

The Antimicrobial Drugs Advisory Committee voted 7-6 that the efficacy results of Solithera outweigh its risks, including hepatotoxicity. Panelists previously...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers